By Chris Wack
Innate Pharma SA said Friday that AstraZeneca has dosed the first patient in its Phase 3 clinical trial evaluating monalizumab in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Dosing of the first patient in the trial has triggered a $50 million milestone payment from AstraZeneca to Innate.
Innate said the milestone payment fortifies its cash position through the end of 2022.
The company said the combination of monalizumab and cetuximab demonstrated a manageable safety profile and a response rate of 27.5%.
Innate Pharma shares were up 12%, to $4.41, in premarket trading.
Write to Chris Wack at email@example.com
(END) Dow Jones Newswires